Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine

Neurology

Volumn 62, Issue 11, 2004, Pages 2044-2050

  Mainero, C ^a,b   Inghilleri, M ^a   Pantano, P ^a   Conte, A ^a   Lenzi, D ^a   Frasca, V ^a   Bozzao, L ^a   Pozzilli, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; ELECTROMYOGRAPHY; EVOKED MUSCLE RESPONSE; FACILITATION; FEMALE; HUMAN; LATENT PERIOD; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; MUSCLE FATIGUE; NERVE CONDUCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RIGHT HANDEDNESS; SENSORIMOTOR CORTEX; SYNAPTIC TRANSMISSION; TASK PERFORMANCE; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 2942596467     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000129263.14219.A8     Document Type: Article

References (45)

1. Bever CT Jr, Leslie J, Camenga DL, Panitch HS, Johnson KP. Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. Ann Neurol 1990;27:421-427.
2. Polman CH, Bertelsmann FW, van Loenen AC, Koetsier JC. 4-Aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety. Arch Neurol 1994;51:292-296.
3. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001;7: 354-358.
4. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998;121: 967-975.
5. Sherratt RM, Bostock H, Sears TA. Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres. Nature 1980;283:570-572.
6. Smith KJ, Felts PA, John GR. Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension. Brain 2000;123:171-184.
7. Pariente J, Loubinoux I, Carel C, et al. Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol 2001;50:718-729.
8. Johansen-Berg H, Dawes H, Guy C, Smith SM, Wade DT, Matthews PM. Correlation between motor improvements and altered fMRI activity after rehabilitative therapy. Brain 2002;125:2731-2742.
9. Filippi M, Rocca MA, Falini A, et al. Correlations between structural CNS damage and functional MRI changes in primary progressive MS. Neuroimage 2002;15:537-546.
10. Pantano P, Iannetti GD, Caramia F, et al. Cortical motor reorganization after a single clinical attack of multiple sclerosis. Brain 2002;125: 1607-1615.
11. Pantano P, Mainero C, Iannetti GD, et al. Contribution of corticospinal tract damage to cortical motor reorganization after a single clinical attack of multiple sclerosis. Neuroimage 2002;17:1837-1843.
12. Reddy H, Narayanan S, Woolrich M, et al. Functional brain reorganization for hand movement in patients with multiple sclerosis: defining distinct effects of injury and disability. Brain 2002;125:2646-2657.
13. Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature 2001; 412:150-157.
14. Kujirai T, Caramia MD, Rothwell JC, et al. Corticocortical inhibition in human motor cortex. J Physiol 1993;471:501-519.
15. Schulze-Bonhage A, Knott H, Ferbert A. Effects of carbamazepine on cortical excitatory and inhibitory phenomena: a study with paired transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol 1996;99:267-273.
16. Chen R, Samii A, Canos M, Wassermann EM, Hallett M. Effects of phenytoin on cortical excitability in humans. Neurology 1997;49:881-883.
17. Liepert J, Schwenkreis P, Tegenthoff M, Malin JP. The glutamate antagonist riluzole suppresses intracortical facilitation. J Neural Transm 1997;104:1207-1214.
18. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
19. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-1452.
20. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993;37:753-762.
21. Van Diemen HA, Polman CH, Koetsier JC, Van Loenen AC, Nauta JJ, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol 1993;16:195-204.
22. Friston KJ, Holmes A, Poline JB, Price CJ, Frith CD. Detecting activations in PET and fMRI: levels of inference and power. Neuroimage 1996;4:223-235.
23. Talairach J, Tournoux P. Coplanar stereotaxic atlas of the human brain. Stuttgart: Thieme, 1988.
24. Grimaud J, Lai M, Thorpe J, et al. Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Res Imag 1996;14:495-505.
25. Inghilleri M, Berardelli A, Cruccu G, Manfredi M. Silent period evoked by transcranial stimulation of the human cortex and cervicomedullary junction. J Physiol 1993;466:521-534.
26. Shimizu T, Hosaki A, Hino T, et al. Motor cortical disinhibition in the unaffected hemisphere after unilateral cortical stroke. Brain 2002;125: 1896-1907.
27. Brown P, Ridding MC, Werhahn KJ, Rothwell JC, Marsden CD. Abnormalities of the balance between inhibition and excitation in the motor cortex of patients with cortical myoclonus. Brain 1996;119:309-317.
28. Lorenzano C, Gilio F, Inghilleri M, et al. Spread of electrical activity at cortical level after repetitive magnetic stimulation in normal subjects. Exp Brain Res 2002;147:186-192.
29. Tapia R, Sitges M. Effect of 4-aminopyridine on transmitter release in synaptosomes. Brain Res 1982;250:291-299.
30. Rudy B. Diversity and ubiquity of K channels. Neuroscience 1988;25: 729-749.
31. Damsma G, Biessels PT, Westerink BH, De Vries JB, Horn AS. Differential effects of 4-aminopyridine and 2,4-diaminopyridine on the in vivo release of acetylcholine and dopamine in freely moving rats measured by intrastriatal dialysis. Eur J Pharmacol 1988;145:15-20.
32. Hu PS, Jin S, Fredholm BB. 4-Aminopyridine-induced noradrenaline release from the rat hippocampus depends on the activation of glutamate receptors of the non-NMDA type. Acta Physiol Scand 1991;143: 139-140.
33. Scheer HW, Lavoie PA. Mechanism of aminopyridine-induced release of [3H]dopamine from rat brain synaptosomes. Gen Pharmacol 1991;22: 169-172.
34. Perreault P, Avoli M. Physiology and pharmacology of epileptiform activity induced by 4-aminopyridine in rat hippocampal slices. J Neurophysiol 1991;65:771-785.
35. Pena F, Bargas J, Tapia R. Paired pulse facilitation is turned into paired pulse depression in hippocampal slices after epilepsy induced by 4-aminopyridine in vivo. Neuropharmacology 2002;42:807-812.
36. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996;40:367-378.
37. Curra A, Modugno N, Inghilleri M, Manfredi M, Hallett M, Berardelli A. Transcranial magnetic stimulation techniques in clinical investigation. Neurology 2002;59:1851-1859.
38. Fuhr P, Agostino R, Hallett M. Spinal motor neuron excitability during the silent period after cortical stimulation. Electroencephalogr Clin Neurophysiol 1991;81:257-262.
39. Werhahn KJ, Kunesch E, Noachtar S, Benecke R, Classen J. Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 1999;517:591-597.
40. Min MY, Melyan Z, Kullmann DM. Synaptically released glutamate reduces gamma-aminobutyric acid (GABA)ergic inhibition in the hippocampus via kainate receptors. Proc Natl Acad Sci USA 1999;96:9932-9937.
41. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13:266-271.
42. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ. An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 1997;120:299-315.
43. Leocani L, Colombo B, Magnani G, et al. Fatigue in multiple sclerosis is associated with abnormal cortical activation to voluntary movement-EEG evidence. Neuroimage 2001;13:1186-1192.
44. Roelcke U, Kappos L, Lechner-Scott J, et al. Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997;48:1566-1571.
45. Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage 2002;15: 559-567.